Company

Bank

Analyst

Coverage

Opinion

Wk chg

4/4 cls

GlycoMimetics Inc. (NASDAQ:GLYC)

Jefferies

Biren Amin

Price target

Buy

4%

$15.77

Amin raised his target to $20 from $13 after GlycoMimetics said it will begin a Phase I trial with GMI-1271 to treat acute myelogenous leukemia (AML) this quarter. The company also expects partner Pfizer Inc. (NYSE:PFE) to begin a Phase III trial evaluating GMI-1070 in patients with vaso-occlusive crisis next quarter. GMI-1271 is an inhibitor of E selectin (SELE; CD62E) and GMI-1070 is a glycomimetic inhibitor of SELE, P selectin (SELP; CD62P) and L selectin (CD62L; SELL).